Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17833080 | 1.00 | DPP4 (0.33) | DPP4 | |
| SCHEMBL1817193 | 0.78 | SLC7A5 (0.38) | DPP4 | |
| SCHEMBL14412626 | 0.78 | GRIN2D (0.34) | — | |
| SCHEMBL19660296 | 0.76 | ALDH1A1 (0.36) | DPP4 | |
| SCHEMBL13577874 | 0.76 | ALOX15 (0.39) | DPP4 | |
| SCHEMBL15623785 | 0.74 | DPP4 (0.42) | DPP4 | |
| SCHEMBL14769893 | 0.73 | ALOX15 (0.44) | DPP4 | |
| SCHEMBL4079531 | 0.73 | ALOX15 (0.44) | DPP4 | |
| SCHEMBL8004357 | 0.73 | ALOX15 (0.44) | DPP4 | |
| SCHEMBL844430 | 0.73 | TSHR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342064-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-30 | — | — | US | disclosed |
| US-20170342064-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-30 | — | — | US | disclosed |
| WO-2016091825-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342064-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | MPST, TK1, BRCA1 | DPP4 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.